Page 22 - Icmr

Bharat Biotech's Covaxin effective against Delta Plus variant: ICMR study

Bharat Biotech's Covid-19 vaccine Covaxin (BBV152) is effective against Delta Plus (AY.1) variant of the coronavirus, according to a study by the Indian Council of Medical and Research

Covaxin effective against Delta Plus Covid variant, says ICMR study

The domestically developed Covaxin is effective against the Delta plus variant of Covid-19, claims Indian Council of Medical Research (ICMR) in its study released on Monday.

Forecasters who predicted India's coronavirus peak see new wave coming

Daily cases have grown persistently through July in Kerala and a few smaller north-eastern states

DATA STORY: Active cases rising; Kerala added over 100,000 cases in 6 days

India has so far administered 461,518,479 vaccine doses. That is 1459.85 per cent of its total caseload, and 33.09 per cent of its population

DATA STORY: Active cases rise for third-day straight; 555 deaths reported

India has so far administered 456,033,754 vaccine doses. That is 1444.4 per cent of its total caseload, and 32.7 per cent of its population

Madhya Pradesh has highest Covid-19 antibodies, Sero Survey data shows

The Central government on Wednesday advised all States and UTs to conduct sero-prevalence surveys in consultation with the Indian Council of Medical Research (ICMR) to generate district-level data.

BS Number Wise: How efficient is India's Covid-19 vaccination programme?

India averages 109 vaccinations per site and the UK 126. It has fully vaccinated only 6 per cent of its population, as against 53 per cent in the UK

DATA STORY: Lowest spike in cases in 132 days; Active cases below 400,000

India has so far administered 441,912,395 vaccine doses. That is 1405.53 per cent of its total caseload, and 31.69 per cent of its population

Do we have enough doctors and nurses to deal with impending third wave?

Coronavirus pandemic has overwhelmed India’s healthcare system. One critical gap doesn’t get attention, though: The country’s acute shortage of doctors and nurses. Watch the video for some crucial data.

DATA STORY: India reports 39,361 new cases, 416 deaths; active cases rise

India has so far administered 435,196,001 vaccine doses. That is 1385.47 per cent of its total caseload, and 31.21 per cent of its population

DATA STORY: 35,342 cases, 483 deaths reported; active cases decline again

India has so far administered 427,882,261 vaccine doses. That is 1365.63 per cent of its total caseload, and 30.68 per cent of its population

Premature to conclude health complications due to Covid-19 rising: Govt

It may be premature to conclude that complications like lung fibrosis and increased thrombotic events due to COVID-19 are on the rise.

DATA STORY: 35,342 cases, 483 deaths reported; active cases decline again

India has so far administered 423,417,030 vaccine doses. That is 1353.07 per cent of its total caseload, and 30.36 per cent of its population

DATA STORY: Active cases rise for 2nd day straight; 507 more deaths added

India has so far administered 417,851,151 vaccine doses. That is 1336.79 per cent of its total caseload, and 29.96 per cent of its population

Increasing infection

Govt should not get complacent about Covid management

Two-thirds of India's population has Covid antibodies: ICMR's serosurvey

Despite high seropositivity shown in data, the government has cautioned that around 400 million people in India were still vulnerable to the virus

Top headlines: 67% of Indians have antibodies; Bezos flies to space

Here are the top headlines of the day

Covid: Can open primary schools if support staff vaccinated, says ICMR

Once India starts reopening schools, it will be wise to being with the primary section as children have a lower number of ace receptors to which virus attaches

Two-thirds of Indians have Covid antibodies, finds ICMR sero survey

A third of the population did not have SARS-CoV-2 antibodies, which means about 400 million people are still vulnerable to Covid infection, says ICMR official

Bharat Biotech had agreed to offer vaccine at reasonable rates to Govt: MoH

ICMR has spent Rs 35 cr on Covaxin clinical trials